Lymphoma

Latest News

Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL
Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL

November 17th 2024

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

BTK Inhibitor Treatment Options Across the Lymphoma Landscape
BTK Inhibitor Treatment Options Across the Lymphoma Landscape

November 17th 2024

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.
Transposon-Engineered BAFF CAR-T Cells May Elicit Responses in Lymphoma

November 13th 2024

3 Things You Should Know About Biomarkers in DLBCL
3 Things You Should Know About Biomarkers in DLBCL

November 11th 2024

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.
Valemetostat Yields Enduring Responses in Relapsed/Refractory PTCL

November 6th 2024

Latest CME Events & Activities